Reimbursement of Medicines. 5 years experience with CRM procedure. SRBGE Brussels Oct 2007
|
|
- Joella Clark
- 8 years ago
- Views:
Transcription
1 Reimbursement of Medicines 5 years experience with CRM procedure SRBGE Brussels Oct 2007 Philippe Van Wilder RIZIV - INAMI Head Reimbursement of Medicines Dept. Disclaimer: The opinions of the author do not necessarily reflect those of the institution he represents 1
2 Structure 1. Market authorisation versus reimbursement decision 2. Reimbursement procedure 3. Reimburement facts & figures 2
3 Product life-cycle 3
4 1. Marketing Authorization versus Reimbursement Evaluation Marketing Application Authorization (MAA) > Reimbursement decision > 1. European Centralized or Mutual Recognition 2. Dossier based on Efficacy Safety Pharmaceutical quality 3. Benefit/risk balance of the drug on its own 1. Per member state 2. Dossier goes beyond MAAelements: + Effectiveness + Convenience + others 3. Relative therapeutic value as compared to alternatives 4. Relative economic value as compared to alternatives C/ E 4
5 Expected to go bankrupt according to this report: US Medicare Trust Fund by 2019 French healthcare system by
6 Data 6
7 2. Reimbursement procedure 7
8 Reimbursement Key Features Positive list based on dossier submitted by applicant Claiming added (class 1 price premium) or similar value (class 2) Reimbursement granted within SPC Reimbursement may be limited to specific subgroups Different reimbursement categories (A B C Cs Cx D) 2 phases in reimbursement procedure: Evaluation of scientific evidence Concrete Reimbursement proposal Conditional listing in case of cl I >>> Review! (18-36m) 8
9 Procedures (Eur Dir 105/89) MA procedure reimbursement reimbursement request day 0 evaluation day 90 proposal day 150 decision day 180 9
10 Composition of the CRM/CTG 30 members 22 voting members : 7 academics 8 sick funds 4 physicians association 3 pharmacists association 8 non voting members : 4 ministry rep. 1 INAMI/RIZIV 2 Pharma.be 1 Febelgen academics sick funds physician's assoc pharmacists assoc non voting members 10
11 Reimbursement Evaluation Process : Belgium MAA > Submission of dossier Econ Aff. CRM D8 Acceptance D30: 1st evaluation D60 main evaluation First Proposal Final Proposal Hearing! (cli) Reimbursement decision Applicant D180: Minister Decision 11
12 Evaluation criteria Therapeutic value Price and proposed reimbursement level Cl III Position of the drug in medical practice (therapeutic and social needs) Cl III Budgetary impact to National Insurance Agency class I only: Efficiency (cost / therapeutic value) 12
13 Therapeutic value Efficacy Safety Effectiveness Applicability Convenience > class I added value > class II comparable value class III copy/generic R.D Dec.21st, 2001 via: = sum of elements As determined by : Morbidity Mortality Quality of life 13
14 Questions addressed by reimbursement procedure: Clinical data (RCT) Epidemiological data Real Life data Health economics data Budget impact data Efficacy controlled setting Effectiveness daily practice Efficiency cost-effective = Can it work? = Does it work? = Is it worthwile? 14
15 Eur member state B Submission for reimbursement in Belgium, France and the Netherlands Elements included in (A)TV: Other: Source: Reimbursement agencies: B RIZIV FR HAS NL CVZ MAA EMEA Efficacy Safety Effectiveness Applicability Convenience Disease severity Experience: Conditional: Added value: 15
16 Class I medicines: Conditional reimbursement / review procedure R.D. of Dec 21st 2001 : Art.16, 62, & 63 Elements & timelines > specified in CRM proposition Timelines: within 18m to 36m Aim = Confirmation y/n of assumptions at initial approval Criteria : Those applicable to therapeutic value assessment but special emphasis on : effectiveness, PE in daily practice Sales volume Reimbursement modalities in European Member States Additional elements: Recent documents/guidelines from CRM Scientific studies (peer reviewed) Yearly cost evolution within therapeutical class Prescribed daily dose Other elements relating to applicability and effectiveness Consensus reports 16
17 3. Reimburement facts & figures 17
18 Belgium, CRM procedure, data Number of unique* finished submissions in the period * unique = same DCI same day0 same decision Year of submission 2002 cl 1 cl 2 cl 3 orphan Type of submission Change in reimburse. other Revision cl 1 Total Total Note: 2006 is an underestimate because only finished files are considered 18
19 Crosstabulation Minister Decision split per type of submission Minister Type of submission Decision N (%) chng rev cl cl 1 cl 2 cl 3 orphan reim other 1 Total pos Count % column 63,0% 76,0% 91,5% 71,4% 64,6% 71,1% 70,6% 77,7% neg Count % column 32,0% 15,2% 2,4% 19,0% 23,0% 15,4% 5,9% 13,2% no dec Count % column 2,0% 5,4% 4,3%,0% 5,5% 13,2%,0% 6,0% closed Count % column,0%,0%,0%,0%,7%,0%,0%,1% missing Count % column 3,0% 3,4% 1,7% 9,5% 6,2%,4% 23,5% 3,1% Total Count Count % row % column 100,0% 100,0% 100,0% 100,0% 100,0% 100,0% 100,0% 19
20 USA : Schultz report to Congress 20
21 USA : Schultz report to Congress 21
22 USA : Schultz report to Congress 22
23 Drop in innovation? 23
24 Drop in innovation? 24
25 Eur member state B Voir site H.A.S. 25
26 Extrait du Rapport INAMI
27 Extrait du Rapport INAMI
28 IMS Health LMPB per ATC main class Euro (PP) A APP DIGESTIF.METABOLISME B SANG.ORGANES HEMATOPOIET C APP. CARDIOVASCULAIRE D DERMATOLOGIE G APP GENIT-URIN.HORM.SEX. H HORMONES J ANTIINFECTIEUX V GENERALE K SOLUTIONS PR HOPITAUX L ANTINEOPLAS..IMMUNOMODUL. M APPAREIL LOCO MOTEUR N SYSTEME NERVEUX P ANTIPARASITAIRES R APPAREIL RESPIRATOIRE S ORGANES DES SENS T AGENTS POUR DIAGNOSTIC V DIVERS 0 JUL 05 SEP 05 N0V 05 JAN 06 MAR 06 MAY 06 JUL 06 SEP 06 NOV 06 JAN 07 MAR 07 MAY 07 JUL 07 Month 28
29 IMS Health BHA: sales per ATC main class Euro (ex fact) QTR3/02 QTR4/02 QTR1/03 QTR2/03 QTR3/03 QTR4/03 QTR1/04 QTR2/04 QTR3/04 QTR4/04 QTR1/05 Quarter QTR2/05 QTR3/05 QTR4/05 QTR1/06 QTR2/06 QTR3/06 QTR4/06 QTR1/07 QTR2/07 V DIVERS T AGENTS POUR DIAGNOSTIC S ORGANES DES SENS R APPAREIL RESPIRATOIRE P ANTIPARASITAIRES N SYSTEME NERVEUX M APPAREIL LOCO MOTEUR L ANTINEOPLAS.,IMMUNOMODUL. K SOLUTIONS PR HOPITAUX J ANTIINFECTIEUX V GENERALE H HORMONES G APP GENIT-URIN.HORM.SEX. D DERMATOLOGIE C APP. CARDIOVASCULAIRE B SANG,ORGANES HEMATOPOIET A APP DIGESTIF,METABOLISME 29
30 Officine ouverte: dépenses INAMI 30
31 Officine hospitalière: ventes IMS 31
32 Thank you! Philippe Van Wilder RIZIV Reimbursement of Medicines 32
Evaluation reports from the Commission on Reimbursement of Medicines (CRM) and the Medical Pharmaceutical Committee (MFC) as specific target group
Evaluation reports from the Commission on Reimbursement of Medicines (CRM) and the Medical Pharmaceutical Committee (MFC) as specific target group Philippe Van Wilder RIZIV-INAMI Belgian National Health
More informationAT&T Global Network Client for Windows Product Support Matrix January 29, 2015
AT&T Global Network Client for Windows Product Support Matrix January 29, 2015 Product Support Matrix Following is the Product Support Matrix for the AT&T Global Network Client. See the AT&T Global Network
More informationModerator: J van Loon,MSc Mapi. Advisor to the President, Head of International Affairs, HAS France
Comparing the challenges of comparative effectiveness Research in France, Italy and the Netherlands Current Situation and Perspectives Issue Panelists: F. Meyer, MD Advisor to President, France E. Xoxi,
More informationCOMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*
COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun
More informationCOMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*
COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun
More informationthe compulsory health care insurance. A kaleidoscopic view. Chris Segaert NIHDI Dept. of health care Dir. International relations
The Health lhcare System in Belgium : the compulsory health care insurance. A kaleidoscopic view. Chris Segaert NIHDI Dept. of health care Dir. International relations 1 Summary I. Introduction II. III.
More informationComité Economique des Produits de Santé
Comité Economique des Produits de Santé Summary of the activity report for 1999 CEPS 8 avenue de Ségur 75350 Paris SP 07 Activity Report for 1999 1 In accordance with Article D.162-2-5 of the Social Security
More informationhttp://www.mig.tu-berlin.de
Post-licensing evaluation of new medicines 25 20 15 10 A valuable tool to foster true pharmaceutical innovations? An international perspective Dr. Annette Zentner MD, MPH Dept. Health Care Management Rationale
More informationThe fourth hurdle system. International HTA agencies. Australian PBAC. Difference between health technology regulatory body and HTA body
* This presentation is prepared by the author in one s personal capacity for the purpose of academic exchange and does not represent the views of his/her organisations on the topic discussed. Local Application
More information2015-16 BCOE Payroll Calendar. Monday Tuesday Wednesday Thursday Friday Jun 29 30 Jul 1 2 3. Full Force Calc
July 2015 CM Period 1501075 July 2015 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 August 2015 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
More informationRed blood cell transfusions in the Netherlands Towards (very) low use
Red blood cell transfusions in the Netherlands Towards (very) low use Marian G.J. van Kraaij, MD PhD hematologist/ transfusion medicine specialist Director Dept Transfusion Medicine Sanquin Blood Supply,
More informationHow To Understand The Paediatric Regulation
Paediatric Use Marketing Authorisation (PUMA) from a National Competent Authority Point of View DGRA Annual Congress 2006 Bonn, 10. May 2006 Dr. Susanne Keitel Content PUMA The Future Background Legislative
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, EMA Brussels, 27.03.2014 ENTR/6283/00 Rev 4 orphan\guidelines\format content
More informationCase 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138. Exhibit 8
Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138 Exhibit 8 Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 2 of 138 Domain Name: CELLULARVERISON.COM Updated Date: 12-dec-2007
More informationRegulatory approval routes in the European System for Medicinal Products
Regulatory approval routes in the European System for Medicinal Products Cardiovascular Combination Pharmacotherapy Global Summit, Melbourne, 8 th May 2014 Presented by: Kevin Blake Human Medicines Research
More informationP/T 2B: 2 nd Half of Term (8 weeks) Start: 26-AUG-2013 End: 20-OCT-2013 Start: 21-OCT-2013 End: 15-DEC-2013
2013-2014 SPECIAL TERM ACADEMIC CALENDAR FOR SCRANTON EDUCATION ONLINE (SEOL), MBA ONLINE, HUMAN RESOURCES ONLINE, NURSE ANESTHESIA and ERP PROGRAMS SPECIAL FALL 2013 TERM Key: P/T = Part of Term P/T Description
More informationP/T 2B: 2 nd Half of Term (8 weeks) Start: 25-AUG-2014 End: 19-OCT-2014 Start: 20-OCT-2014 End: 14-DEC-2014
2014-2015 SPECIAL TERM ACADEMIC CALENDAR FOR SCRANTON EDUCATION ONLINE (SEOL), MBA ONLINE, HUMAN RESOURCES ONLINE, NURSE ANESTHESIA and ERP PROGRAMS SPECIAL FALL 2014 TERM Key: P/T = Part of Term P/T Description
More informationP/T 2B: 2 nd Half of Term (8 weeks) Start: 24-AUG-2015 End: 18-OCT-2015 Start: 19-OCT-2015 End: 13-DEC-2015
2015-2016 SPECIAL TERM ACADEMIC CALENDAR For Scranton Education Online (SEOL), Masters of Business Administration Online, Masters of Accountancy Online, Health Administration Online, Health Informatics
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 19 July 2007 Doc. Ref: EMEA/27170/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON COMPASSIONATE USE OF MEDICINAL
More informationEU Pricing & Reimbursement
EU Pricing & Reimbursement Pricing & reimbursement schemes in major European countries Contents Introduction 1 Belgium 2 The Czech Republic 8 Germany 13 France 23 NOVEMBER Italy 30 The Netherlands 35 Spain
More informationREGULATION. on the advertising of medicinal products. SECTION I Definitions, scope and general provisions.
REGULATION on the advertising of medicinal products. SECTION I Definitions, scope and general provisions. Article 1 Definitions. For the purposes of this Regulation, the following terms are used as defined
More informationTemplate for essential information to be provided for proposals including clinical trials / studies / investigations
Template for essential information to be provided for proposals including clinical trials / studies / investigations Document history Version 2016callsV1 September 2015 Modifications (compared to previous
More informationAnalysis of Hospital Pharmaceuticals
Danish Ministry of Health and Prevention Analysis of Hospital Pharmaceuticals Country Report - Germany March 2009 COWI A/S Parallelvej 2 DK-2800 Kongens Lyngby Denmark Tel +45 45 97 22 11 Fax +45 45 97
More informationAnalysis One Code Desc. Transaction Amount. Fiscal Period
Analysis One Code Desc Transaction Amount Fiscal Period 57.63 Oct-12 12.13 Oct-12-38.90 Oct-12-773.00 Oct-12-800.00 Oct-12-187.00 Oct-12-82.00 Oct-12-82.00 Oct-12-110.00 Oct-12-1115.25 Oct-12-71.00 Oct-12-41.00
More informationAgence fédérale des médicaments et des produits de santé
Agence fédérale des médicaments et des produits de santé From Risk Management Plan to Risk Minimization Activities New Royal Decree: Status and General Explanation Role of the Pharmacovigilance Department
More informationEnhanced Vessel Traffic Management System Booking Slots Available and Vessels Booked per Day From 12-JAN-2016 To 30-JUN-2017
From -JAN- To -JUN- -JAN- VIRP Page Period Period Period -JAN- 8 -JAN- 8 9 -JAN- 8 8 -JAN- -JAN- -JAN- 8-JAN- 9-JAN- -JAN- -JAN- -JAN- -JAN- -JAN- -JAN- -JAN- -JAN- 8-JAN- 9-JAN- -JAN- -JAN- -FEB- : days
More informationBelgian Health system. Salvador, December 3d 2012
Belgian Health system Salvador, December 3d 2012 2 Belgium odifiez les styles du texte du masque Belgium 4 11 millions inhab (2012) 353 hab/km2 3 communities (3 langages), 3 regions GDP per capita : 38200$
More informationEmployers Compliance with the Health Insurance Act Annual Report 2015
Employers Compliance with the Health Insurance Act Annual Report 2015 ea Health Council Health Council: Employers Compliance with the Health Insurance Act 1970 Annual Report 2015 Contact us: If you would
More informationMeaningful Use: Driving Physicians to eprescribing/emr and Pharma Marketing Opportunities
Meaningful Use: Driving Physicians to eprescribing/emr and Pharma Marketing Opportunities Devin Paullin EVP, New Business Development Physicians Interactive Dan Pucci Director, Informatics Solutions Allscripts
More informationActivities In accordance with the applicable rules of law, particularly competition
SNITEM SNITEM profile SNITEM the leading trade organisation, was set up in 1987 It draws together more than 315 companies SNITEM estimated that its scope (medical device and Healthcare ICT markets) corresponded
More informationA Belgian cooperation platform www.coopami.org. Thomas Rousseau NIHDI - COOPAMI. Thomas Rousseau
A Belgian cooperation platform www.coopami.org Thomas Rousseau NIHDI - COOPAMI Thomas Rousseau NIHDI 14-01-2013 - COOPAMI 2 Contributif Social security What i m going to talk about Presentation: only on
More informationPlease find below some views on the issues raised by the EMA Senior Medical Officer's Reflections on the legal basis for EMA/CHMP opinions.
Jacques Ropers Afssaps Pierre Demolis Afssaps (French CHMP Member) Philippe Lechat Afssaps (French Alternate CHMP Member) Dear Colleagues, Please find below some views on the issues raised by the EMA Senior
More informationTERMS USED IN FINANCIAL STATISTICAL REPORTS (FSRs)
TERMS USED IN FINANCIAL STATISTICAL REPORTS (FSRs) Total Member Months - Number of members enrolled in each month. YTD is the sum of the individual month s membership. Revenues: Premiums Capitation payments
More informationIs it time for a new drug development paradigm?
Is it time for a new drug development paradigm? Robert McDonough, M.D. Senior Director, Clinical Policy Research and Development 1 The Aetna Way Our Cause To make quality health care more affordable and
More informationElectronic medical records
Electronic medical records Country: France Partner Institute: Institut de Recherche et Documentation en Economie de la Santé (IRDES), Paris Survey no: (8)2006 Author(s): Chantal Cases, Philippe Le Fur
More informationTemporary Authorisations for Use (ATU)
AGENCE FRANCAISE DE SECURITE SANITAIRE DES PRODUITS DE SANTE DIVISION FOR THE EVALUATION OF MEDICINAL AND BIOLOGICAL PRODUCTS Department of Products with a specific Status, Information, Therapeutic Recommendations
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)
European Medicines Agency Veterinary Medicines and Inspections London, 18 May 2006 Doc. Ref. EMEA/CVMP/32995/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) GUIDELINE ON THE PROCEDURE FOR
More informationLessons learnt from initiatives in the Netherlands
Lessons learnt from initiatives in the Netherlands Dutch Steering Committee on Orphan Drugs Frits Lekkerkerker Chairman 1 The start Recommendations of the Advisory Council on Health Research (RGO) in 1998
More informationS P E C I A L I S T A N D M A S T E R S T U D I E S
University Ss, Cyril and Methodius Skopje FACULTY OF PHARMACY S P E C I A L I S T A N D M A S T E R S T U D I E S Healthcare management and pharmacoeconomics Skopje, 2007 STUDY PLAN -Specialist Studies-
More informationPL 17871/0208 UKPAR TABLE OF CONTENTS
Fultium-D 3 3,200 IU Capsules PL 17871/0208 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 11 Summary of Product Characteristics Page 12 Patient
More informationFormulary Management
Formulary Management Formulary management is an integrated patient care process which enables physicians, pharmacists and other health care professionals to work together to promote clinically sound, cost-effective
More informationFrench pharmaceutical system Focus on pricing and reimbursement
Couverture French pharmaceutical system Focus on pricing and reimbursement DDGOS date Sophie DELCROIX-LOPES CNAMTS Conflict of interest disclosure 2 The author declares that she has no competing interests.
More informationSafe Harbor Statement Writing - Cologuard Cancer
Third-Quarter 2015 Earnings Call October 29, 2015 Safe Harbor statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the Securities
More informationPricing and Reimbursement Questions
Pricing and Reimbursement Questions INTRODUCTION This work endeavors to provide a concise and practical comparative guide on the current status of pricing and reimbursement of medicinal products for human
More informationComparison of Healthcare Systems in Selected Economies Part I
APPENDIX D COMPARISON WITH OVERSEAS ECONOMIES HEALTHCARE FINANCING ARRANGEMENTS Table D.1 Comparison of Healthcare Systems in Selected Economies Part I Predominant funding source Hong Kong Australia Canada
More informationOPTIMIZING SCIENTIFIC VALUE: SMART AND SYSTEMATIC APPROACHES TO MEDICAL PUBLICATIONS
OPTIMIZING SCIENTIFIC VALUE: SMART AND SYSTEMATIC APPROACHES TO MEDICAL PUBLICATIONS April 27 29, 2015 Hyatt Regency Crystal City Arlington, VA, USA 11TH ANNUAL MEETING OF ISMPP 1 ORGANIZED HEALTHCARE
More informationPreventive health-care system in France : Organisation, financement
Preventive health-care system in France : Organisation, financement Dr Martine Le Quellec-Nathan Sous-directrice Direction générale de la Santé Ministère de la santé et de la protection sociale VHPB Veyrier
More informationIntegration of Pharmacists Clinical Services in the Patient-Centered Primary Care Medical Home. March 2009
Integration of Pharmacists Clinical Services in the Patient-Centered Primary Care Medical Home March 2009 Introduction: The potential promise and value of the patient-centered primary care medical home
More informationDHS BUDGET REQU~ST FOR FY 2015-2016
DHS BUDGET REQU~ST FOR FY 2015-2016 ($ Amounts in Thousands) Page # of Governor's Executive Budget: APPROPRIATION: Pp. C1.8, E30.5, E30.16, E30.17 Payment to Federal Govt. - Medicare Drug Progr~m l. SUMMARY
More informationEuropean Regulatory Newsletter July - September 2013
European Regulatory Newsletter July - September 2013 Introduction CROMSOURCE is committed to sharing our expertise with our clients and future clients. This reflects the first part of our Advise Agree
More informationTherapeutic strategies for the treatment of pain
First EFIC Symposium - Societal Impact of Pain Brussells 4-5 May 2010 Therapeutic strategies for the treatment of pain Paolo D. Siviero Economic Strategy and Pharmaceutical Policy Department Office for
More informationPatient Support Programs and Market Research Programs in Pharmacies: Managing Safety Information
Patient Support Programs and Market Research Programs in Pharmacies: Managing Safety Information Suzete Costa Pharm D, MPH Executive Director of the Centre for Health Evaluation & Research (CEFAR) National
More informationAn Aggregate Reserve Methodology for Health Claims
An Aggregate Reserve Methodology for Health Claims R = P M M Unpaid Paid F F Upaid Paid Where: R = The estimated claim reserve P = Observed paid claims M Paid, M Unpaid = Portion of exposure basis that
More informationThis presentation contains forward-looking statements (made pursuant to the safe harbour provisions of the Private
Safe Harbour Statement This presentation contains forward-looking statements (made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995). By their nature, forward-looking
More informationDonepezil hydrochloride 10 mg film-coated tablets PL 19156/0130
Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 12 Summary of Product Characteristics
More informationMACROGOL COMPOUND ORAL POWDER (sodium chloride, sodium hydrogen carbonate, potassium chloride, macrogol 3350) PL 33579/0001 UKPAR TABLE OF CONTENTS
MACROGOL COMPOUND ORAL POWDER (sodium chloride, sodium hydrogen carbonate, potassium chloride, macrogol 3350) PL 33579/0001 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps
More informationMarketing Authorisation: The Evaluation Process
1 st EMEA Workshop for Micro, Small and Medium- Sized Enterprises (SMEs) Navigating the Regulatory Maze Marketing Authorisation: The Evaluation Process Dr Evdokia Korakianiti Scientific Administrator Centralised
More informationThe Importance of Care Coordination: The Partnerships
The Importance of Care Coordination: The Partnerships Partnerships for Health for Health Experience A Chronic Disease Prevention and Management Demonstration Project Mike Hindmarsh: Project Leadership
More informationPortfolio Management An Inexact Science. Mark Lawry Portfolio Management Dir, GSK Milan, September 2010
Portfolio Management An Inexact Science Mark Lawry Portfolio Management Dir, GSK Milan, September 2010 1 Portfolio Management Vision Optimizing the value delivered from the portfolio in line with strategy
More informationReporting, Re-Contracting and Settlement
US HEALTH AND LIFE INSURANCE UNDERWRITING ADMINISTRATION Simple. Seamless. SafeGuard Self-Funding Reporting, Re-Contracting and Settlement The SafeGuard Self-Funding Timeline Ÿ Although SafeGuard Self-Funding
More informationAnnexure B: Planning, Budgeting and Performance Management Programme
Annexure B:, Budgeting Programme The following are key activities that need take place in more detail than Time frame Nature Period referred Start Finish 2012/09/01 /08/31 /or September /09/01 /09/26 August
More informationDecentralised Procedure. Public Assessment Report
Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report ben-u-ron direkt Erdbeer/Vanille 250/500 mg Granulat in Beuteln ben-u-ron direkt Cappuccino 500/1000
More informationNatalie Pons, Senior Vice President, Assistant General Counsel, Health Care Services. CVS Caremark Corporation
Prepared Statement of Natalie Pons, Senior Vice President, Assistant General Counsel, Health Care Services CVS Caremark Corporation Before the Subcommittee on Regulatory Reform, Commercial and Antitrust
More informationQ1 2010 Results Analyst Presentation Henk van Dalen, CFO 3 May 2010
Q1 2010 Results Analyst Presentation Henk van Dalen, CFO 3 May 2010 Overall trading conditions continue to improve GROUP Operating income 251 million ( 163 million in Q1 20); quarter benefited from four
More informationSeptember 6-8. San Francisco, California 1. CLEAR 2012 Annual Educational Conference Medical Marijuana: Politics Meets Regulation
Medical Marijuana: Politics Meets Regulation Presenters: Dr. Heidi Oetter, MD President, Federation of Medical Regulatory Authorities of Canada Richard Morales, Section Director Colorado Division of Professions
More informationCost Recovery Annual Report
Cost Recovery Annual Report March 2014 Trawl Rationalization Program Fishing Year 2013 and Calculation for 2014 U.S. Department of Commerce National Oceanic and Atmospheric Administration National Marine
More informationCAFIS REPORT 2015.10
CAFIS REPORT 2015.10 INDEX Message CAFIS Inbound 03-06 07-08 CAFIS Arch 09-10 CAFIS Brain 11-12 CAFIS Global 13-14 What We Do 15-16 About CAFIS 17-18 Services for Member Stores 19-34 Services for Card
More informationFrench National Agency for Medicines and Health Products Safety (ANSM) :
French National Agency for Medicines and Health Products Safety (ANSM) : Reinforcing the collaboration with healthcare professionals and patient associations Dany BONNET Scientific information manager
More informationOverview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.
Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey. Céline Dartois, Karl Brendel, Emmanuelle Comets, Céline Laffont, Christian Laveille, Brigitte Tranchand,
More informationObjectives. P&T Committee. P&T Committee Structure. Utilization of P&T Committees
Objectives Discuss overview of forum purpose. Drug Information used in the Managed Care Pharmacy P&T Decision Making Process: Current Practice and Insights Diana Brixner, RPh, PhD Professor and Chair,
More informationGOING TO MARKET Marketing Concepts for Mentoring Programs
GOING TO MARKET Marketing Concepts for Mentoring Programs BY BARBARA E. WEBSTER, M.N.A. What is Marketing?... 1 Key Concept #1: The Customer is the Center of the Universe... 2 Key Concept #2: Market Segmentation...
More informationMeasles and rubella monitoring
SURVEILLANCE REPORT Measles and rubella monitoring February 213 Measles and rubella are targeted for elimination in Europe by 215. ECDC closely monitors progress towards interruption of endemic transmission
More informationMANAGEMENT INFORMATION REPORT Department for Business Innovations & Skills (BIS)
MANAGEMENT INFORMATION REPORT Department for Business Innovations & Skills (BIS) Version 3.2 9/1/215 Clyde & Co 4 th Floor, Collingwood House, 3 Collingwood Street, Newcastle, NE1 1JW T: 191 229 223 F:
More informationStandard Summary Project Fiche IPA centralised programmes
Standard Summary Project Fiche IPA centralised programmes Project number 15: Implementation of Hospital Information System (HIS) 1 BASIC INFORMATION 1.1 CRIS Number: 2008/020-406 1.2 Title: Implementation
More informationThe purpose of this report is to provide the Joint Consultative Committee, for its interest and information, with an update on the absence statistics.
NORTH LANARKSHIRE COUNCIL REPORT To: Joint Consultative Committee for Local r Government Employees From: Head of Human Resources Date: 16 November 2012 Ref: IW/TB/HL Subject: Absence Statistics - Quarter
More informationThe Impact of Medicare Part D on the Percent Gross Margin Earned by Texas Independent Pharmacies for Dual Eligible Beneficiary Claims
The Impact of Medicare Part D on the Percent Gross Margin Earned by Texas Independent Pharmacies for Dual Eligible Beneficiary Claims Angela Winegar, M.S., Marvin Shepherd, Ph.D., Ken Lawson, Ph.D., and
More informationPEDIATRIC MEDICINES: GLOBAL MARKETS
PEDIATRIC MEDICINES: GLOBAL MARKETS PHM170A October 2014 Dr. Cheryl Lee Barton Project Analyst ISBN: 1-56965-971-0 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationEMEA RM DRAFT GUIDANCE ISPE RESPONSE 1
EMEA RM DRAFT GUIDANCE ISPE RESPONSE 1 October 4, 2005 Guideline on Risk Management Systems for Medicinal Products for Human Use DRAFT London, 6 September 2005. This guideline will be included as chapter
More informationInfographics in the Classroom: Using Data Visualization to Engage in Scientific Practices
Infographics in the Classroom: Using Data Visualization to Engage in Scientific Practices Activity 4: Graphing and Interpreting Data In Activity 4, the class will compare different ways to graph the exact
More informationRAPID ALERT SYSTEM (RAS) IN PHARMACOVIGILANCE
3BC6a RAPID ALERT SYSTEM (RAS) IN PHARMACOVIGILANCE Guideline Title Rapid Alert System (RAS) in Pharmacovigilance Legislative basis Directive 65/65/EEC as amended, Council Regulation 2309/93 Date of first
More informationImpact of Health Reform on Prescription Drugs
Impact of Health Reform on Prescription Drugs 1 Indirect Effects Increased Rx Volume = More Prescriptions! Page 2 Retiree Drug Subsidy (RDS) Before HCR Tax-Free Subsidy RDS as taxdeductible income After
More informationBayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups
Open Innovation@BayerHealthCare Dr. Daniel Forler External Innovation Therapeutics Global Drug Discovery, Bayer HealthCare ASTP-Proton Conference Page 1 Bayer Invests Heavily in R&D and is committed to
More informationCENTERPOINT ENERGY TEXARKANA SERVICE AREA GAS SUPPLY RATE (GSR) JULY 2015. Small Commercial Service (SCS-1) GSR
JULY 2015 Area (RS-1) GSR GSR (LCS-1) Texarkana Incorporated July-15 $0.50690/Ccf $0.45450/Ccf $0.00000/Ccf $2.85090/MMBtu $17.52070/MMBtu Texarkana Unincorporated July-15 $0.56370/Ccf $0.26110/Ccf $1.66900/Ccf
More informationThe objectives of the Sri Lankan National Medicinal Drug Policy are
NATIONAL MEDICINAL DRUG POLICY FOR SRI LANKA Preamble Sri Lanka had a partly written Drug Policy from the 1960s. It was written as elements of a policy, beginning from selection of drugs for the government
More informationIntroduction to ICD-10. Frederic F. Little, MD Department of Medicine ICD-10 Physician Champion Boston Medical Center
Introduction to ICD-10 Frederic F. Little, MD Department of Medicine ICD-10 Physician Champion Boston Medical Center Outline ICD-10 and BMC History and Background Physician Impact ICD-10 transition: General
More informationComparative Health Care Systems. Folland et al Chapters 22
Comparative Health Care Systems. Folland et al Chapters 22 Chris Auld Economics 317 March 23, 2012 Health Care Systems. There are many different forms of health care delivery in place in different countries.
More informationAshley Institute of Training Schedule of VET Tuition Fees 2015
Ashley Institute of Training Schedule of VET Fees Year of Study Group ID:DECE15G1 Total Course Fees $ 12,000 29-Aug- 17-Oct- 50 14-Sep- 0.167 blended various $2,000 CHC02 Best practice 24-Oct- 12-Dec-
More informationEMA Update Clinical Trials
EMA Update Clinical Trials Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency 16 October 2012 An agency of the European Union Disclaimer The views presented in this presentation/these
More informationITINERA INSTITUTE ANALYSIS
ITINERA INSTITUTE ANALYSIS LP OREM RIVATE IPSUM EXPENDITURE DOLOR SIT ON AMET, HEALTH CONSECTETUER IN BELGIUM ADIPISCING ELIT 2012/4 18 04 2012 SOCIETY PROSPERITY PROTECTION Summary * In this Itinera paper,
More informationEDITION 2015 TREND REPORT MARCHÉ CIBLE PARIS
EDITION 15 TREND REPORT MARCHÉ CIBLE PARIS Février 15 5, rue Dombasle - 7515 Paris - Tél. : 1 56 56 87 87 Fax : 1 56 56 87 88 - www.mkg-hospitality.com Completed in April 15 HOTEL SUPPLY / OFFRE HÔTELIERE
More informationWork Injury: Benefits, 2010
Austria Belgium Temporary disability The insured receives the cash sickness benefit until a decision on permanent disability is made. The employer pays 100% of earnings for up to 12 weeks (plus additional
More informationMapping quality assurance approaches in Europe
Mapping quality assurance approaches in Europe Reinhard Busse (with Helena Legido-Quigley & Martin McKee) Professor of Health Care Management, Technische Universität Berlin European Observatory on Health
More informationThe Partnership for Patients Rebalancing Health Care 5 Tom Evans, MD November 13, 2012
The Partnership for Patients Rebalancing Health Care 5 Tom Evans, MD November 13, 2012 100 E. Grand Ave., Ste. 360 Des Moines, IA 50309-1835 Office: 515.283.9330 Fax: 515.698.5130 www.ihconline.org Sustainability
More informationThe New Prior Approval Rate Application Process Frequently Asked Questions
The New Prior Approval Rate Application Process Frequently Asked Questions 1. We understand that a complete underwriting manual must be filed electronically in SERFF with each private passenger automobile
More informationOVERVIEW OF IPTR AND NON-FORMULARY PROCESS IN THE ACUTE SECTOR
5.2: POLICY FOR THE MANAGEMENT OF INDIVIDUAL PATIENT TREATMENT REQUESTS IMPORTANT NOTE: This policy document is subject to review pending the introduction of the Peer Approval Clinical System which will
More informationHealth Insurance Exchange Finance Work Group Meeting August 22, 2012 Wakely Consulting Model Table Summaries - Updated
Table 3 Model Take up rate estimates 2014 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Revised 25.0% 25.0% 18.0% 3.6% 3.6% 3.6% 3.6% 3.6% 3.6% 3.6% 3.6% 3.6% Fast 12.0% 18.0% 20.0% 18.0% 6.0% 4.0% 4.0%
More information163rd General Report of the Belgian Court of Audit, presented to the House of Representatives on November 6, 2006.
163rd General Report of the Belgian Court of Audit, presented to the House of Representatives on November 6, 2006. Summary 1 Federal Government budget implementation Filing of the Federal Government general
More informationQUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES
QUESTIONS AND ANSWERS ABOUT THE EDQM ACTIVITIES Why are Pharmacopoeias so important in a globalised world? Pharmacopoeias have historically provided collections of medical recipes intended to ensure accurate
More informationClinical trials: from European perspective to National implementation. CTFG / FAMHP / pharma.be. Brussels, 19 November 2010
Clinical trials: from European perspective to National implementation CTFG / FAMHP / pharma.be Brussels, 19 November 2010 Safety in clinical trials: From detection to decision How safety events are captured
More informationCross-Border Fragmentation of Global OTC Derivatives: An Empirical Analysis
Research Note Cross-Border Fragmentation of Global OTC Derivatives: An Empirical Analysis January 214 Summary In December 2, ISDA published Footnote 88 and Market Fragmentation: An ISDA Survey ( the Survey
More information